Food and Drug Administration-Approved Treatments for Acute Bipolar Depression: What We Have and What We Need
- PMID: 32639285
- DOI: 10.1097/JCP.0000000000001227
Food and Drug Administration-Approved Treatments for Acute Bipolar Depression: What We Have and What We Need
References
-
- Parker G, Fletcher K. Differentiating bipolar I and II disorders and the likely contribution of DSM-5 classification to their cleavage. J Affect Disord. 2014;152-154:57–64.
-
- Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64:543–552.
-
- Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–537.
-
- Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–269.
-
- Miller S, Dell'Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(suppl 1):S3–S11.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
